Enlivex Therapeutics Gestione
Gestione criteri di controllo 1/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Oren Hershkovitz
Amministratore delegato
n/a
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | 5yrs |
| Proprietà del CEO | 0.1% |
| Durata media del management | 5yrs |
| Durata media del Consiglio di amministrazione | 2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
Sep 13
We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully
Apr 04Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Dec 13Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
Jul 25Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?
Apr 05Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Nov 16Enlivex Therapeutics: A Very Enticing Early-Stage Biotech
Sep 30Enlivex to gets US patent covering use of cell therapy Allocetra
Sep 06Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells
Aug 29Envilex Therapeutics reports Q2 results
Aug 22We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Jul 08Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment
Jul 06We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Mar 23Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Nov 25We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Aug 12Enlivex issued European patent covering therapeutic compositions of Allocetra immunotherapy
Jun 15Enlivex issued new Canadian patent for Allocetra immunotherapy
Jun 01We're Not Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn
Apr 29Enlivex shares rise 20% on positive Allocetra data in COVID-19
Feb 03Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Jan 11
Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?
Nov 19Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$22m |
| Mar 31 2024 | n/a | n/a | -US$26m |
| Dec 31 2023 | n/a | n/a | -US$29m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | n/a | n/a | -US$31m |
| Sep 30 2022 | n/a | n/a | -US$29m |
| Jun 30 2022 | n/a | n/a | -US$26m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | n/a | n/a | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$16m |
| Jun 30 2021 | n/a | n/a | -US$14m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | n/a | n/a | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$9m |
| Jun 30 2020 | n/a | n/a | -US$9m |
| Mar 31 2020 | n/a | n/a | -US$8m |
| Dec 31 2019 | US$296k | US$38k | -US$10m |
Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Oren sia ragionevole rispetto ad aziende di dimensioni simili nel mercato US.
Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Oren con le performance aziendali.
AMMINISTRATORE DELEGATO
Oren Hershkovitz (47 yo)
5yrs
Mandato
US$295,600
Compensazione
Dr. Oren Hershkovitz, Ph.D. serves as Chief Executive Officer at Enlivex Therapeutics Ltd. since November 16, 2019. Dr. Hershkovitz served for nearly a decade in managerial and executive roles at PROLOR Bi...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 10.8yrs | US$536.00k | 3.62% $ 651.0k | |
| Chief Executive Officer | 5yrs | US$295.60k | 0.12% $ 21.4k | |
| Chief Financial Officer | 8.8yrs | US$132.00k | 0.0088% $ 1.6k | |
| Senior Director of Operations | 2.8yrs | Nessun dato | Nessun dato | |
| Director of HR | 2.8yrs | Nessun dato | Nessun dato |
5.0yrs
Durata media
47yo
Età media
Gestione esperta: Il team dirigenziale di ENLV è esperto e expertise (durata media dell'incarico 5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 10.8yrs | US$536.00k | 3.62% $ 651.0k | |
| Independent Director | 1.6yrs | Nessun dato | Nessun dato | |
| Independent Director | 10.8yrs | Nessun dato | 0.85% $ 152.4k | |
| Clinical Advisor | no data | Nessun dato | Nessun dato | |
| Independent Vice Chairman of the Board | 2.5yrs | Nessun dato | 0% $ 0 | |
| Director | 3.9yrs | Nessun dato | 0.013% $ 2.3k | |
| Clinical Advisor | no data | Nessun dato | Nessun dato | |
| Clinical Advisor | less than a year | Nessun dato | Nessun dato | |
| Clinical Advisor | less than a year | Nessun dato | Nessun dato | |
| Independent Director | 10.8yrs | Nessun dato | 0.024% $ 4.3k | |
| Clinical Advisor | less than a year | Nessun dato | Nessun dato | |
| Clinical Advisor | less than a year | Nessun dato | Nessun dato |
2.0yrs
Durata media
60yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di ENLV non è considerato esperto (durata media del mandato 2 anni), il che suggerisce un nuovo consiglio.